



## Financial Tear Sheet

### Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed five drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and two clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.

BeiGene was established in Beijing in 2010 and listed on the U.S. NASDAQ Global Select Market in February 2016. As of July 2018, the Company had a global team of over 1,300 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.

### Primary IR Contact

Investor Relations  
E-mail:  
[ir@beigene.com](mailto:ir@beigene.com)

### Stock Information

BGNE (American Depositary Shares)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$127.02</b>

Change (%)	▲ 0.02 (0.02%)
Volume	933,655
52 Week High	\$220.10
52 Week Low	\$77.54
Market Cap	\$98,105,571,632
Rolling EPS	-9.61
PE Ratio	0
Shares Outstanding	772,363,184

Data as of 11/16/18 4:00 p.m. ET

## Press Releases

November 16, 2018

[BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology](#)

---

November 15, 2018

[Priority Review Granted to BeiGene's New Drug Applications for Zanubrutinib and Tislelizumab in China](#)

---

November 13, 2018

[BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

---

## SEC Filings

Filing Date	Form
11/13/18	<a href="#">4</a>
11/08/18	<a href="#">DEF 14A</a>
11/08/18	<a href="#">10-Q</a>
11/07/18	<a href="#">8-K</a>

Data provided by Nasdaq. Minimum 15 minutes delayed.

## Upcoming Events

There are currently no events scheduled.

## Corporate Governance

### Governance Documents

---

 [Code of Business Conduct and Ethics](#)

---

 [Corporate Governance Guidelines](#)

---

 [Securityholder Communication Policy](#)

---

### Committee Charters

---

 [Audit Committee](#)

---

 [Compensation Committee](#)

---

 [Nominating and Corporate Governance Committee](#)

---